Konark Malhotra1, Apostolos Safouris2, Nitin Goyal3, Adam Arthur4, David S Liebeskind5, Aristeidis H Katsanos6, João Sargento-Freitas7, Marc Ribo8, Carlos Molina8, Jong-Won Chung9, Oh Young Bang9, Georgios Magoufis10, Ahmad Cheema4, Steven J Shook11, Ken Uchino11, Andrei V Alexandrov3, Georgios Tsivgoulis12. 1. Department of Neurology, Charleston Area Medical Center, West Virginia University-Charleston Division, Charleston, WV, USA. 2. Second Department of Neurology, National & Kapodistrian University of Athens, "Attikon" University Hospital, Athens, Greece; Stroke Unit, Metropolitan Hospital, Piraeus, Greece. 3. Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA. 4. Department of Neurosurgery, Semmes-Murphey Neurologic and Spine Institute, University of Tennessee Health Science Center, Memphis, TN, USA. 5. Neurovascular Imaging Research Core and UCLA Stroke Center, Department of Neurology, University of California, Los Angeles, CA, USA. 6. Second Department of Neurology, National & Kapodistrian University of Athens, "Attikon" University Hospital, Athens, Greece; Department of Neurology, University of Ioannina School of Medicine, Ioannina, Greece. 7. Department of Neurology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Faculty of Medicine, University of Coimbra, Coimbra, Portugal. 8. Vall D´Hebron Stroke Unit, Hospital Universitari Vall D´Hebron Passeig Vall D´Hebron, Barcelona, Spain. 9. Department of Neurology, Samsung Medical Center, Seoul, South Korea. 10. Department of Interventional Neuroradiology, Metropolitan Hospital, Piraeus, Greece. 11. Department of Neurology, Cleveland Clinic Foundation, Cleveland, OH, USA. 12. Second Department of Neurology, National & Kapodistrian University of Athens, "Attikon" University Hospital, Athens, Greece; Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA. Electronic address: tsivgoulisgiorg@yahoo.gr.
Abstract
BACKGROUND AND AIMS: Statin pretreatment (SP) is associated with improved outcomes in acute ischemic stroke (AIS) patients. Collateral circulation status and final infarct volume (FIV) are independent predictors of functional outcome in AIS. METHODS: We sought to evaluate the association of SP with collateral circulation and FIV in AIS patients. We used a random-effects model for all the analyses, and pooled standardized mean differences (SMDs) and odds ratios (OR) on the FIV and collateral status according to SP history, respectively. RESULTS: We identified 9 eligible studies (1186 AIS patients). History of SP was associated with lower FIV (SMD = 0.25, 95%CI: 0.07-0.42, p = 0.005) compared to negative history of SP. A trend towards good collateral scores was observed in the SP group (OR = 1.45; 95% CI, 0.92-2.29, p = 0.11). Subgroup analysis demonstrated reduced FIV among atherosclerotic stroke patients with history of SP (SMD = 0.49; 95% CI, 0.19-0.80, p = 0.001). CONCLUSIONS: SP appears to be associated with decreased FIV, especially in atherosclerotic AIS.
BACKGROUND AND AIMS: Statin pretreatment (SP) is associated with improved outcomes in acute ischemic stroke (AIS) patients. Collateral circulation status and final infarct volume (FIV) are independent predictors of functional outcome in AIS. METHODS: We sought to evaluate the association of SP with collateral circulation and FIV in AISpatients. We used a random-effects model for all the analyses, and pooled standardized mean differences (SMDs) and odds ratios (OR) on the FIV and collateral status according to SP history, respectively. RESULTS: We identified 9 eligible studies (1186 AISpatients). History of SP was associated with lower FIV (SMD = 0.25, 95%CI: 0.07-0.42, p = 0.005) compared to negative history of SP. A trend towards good collateral scores was observed in the SP group (OR = 1.45; 95% CI, 0.92-2.29, p = 0.11). Subgroup analysis demonstrated reduced FIV among atherosclerotic strokepatients with history of SP (SMD = 0.49; 95% CI, 0.19-0.80, p = 0.001). CONCLUSIONS:SP appears to be associated with decreased FIV, especially in atherosclerotic AIS.
Authors: Konark Malhotra; Nitin Goyal; Aristeidis H Katsanos; Angeliki Filippatou; Eva A Mistry; Pooja Khatri; Mohammad Anadani; Alejandro M Spiotta; Else Charlotte Sandset; Amrou Sarraj; Georgios Magoufis; Christos Krogias; Lars Tönges; Apostolos Safouris; Lucas Elijovich; Mayank Goyal; Adam Arthur; Andrei V Alexandrov; Georgios Tsivgoulis Journal: Hypertension Date: 2020-01-13 Impact factor: 10.190
Authors: Patrick T Ronaldson; Hrvoje Brzica; Wazir Abdullahi; Bianca G Reilly; Thomas P Davis Journal: J Pharmacol Exp Ther Date: 2020-11-09 Impact factor: 4.030
Authors: S Nannoni; F Ricciardi; D Strambo; G Sirimarco; M Wintermark; V Dunet; P Michel Journal: AJNR Am J Neuroradiol Date: 2021-01-28 Impact factor: 3.825
Authors: Stanley Hughwa Hung; Sharon Kramer; Emilio Werden; Bruce C V Campbell; Amy Brodtmann Journal: Front Neurol Date: 2022-02-15 Impact factor: 4.003